Page 45 - Haematologica May 2022

HCT worldwide access
and assured quality of the data given to the analysis; HB, DN, MP, and LF analysed data; DN, HB, WS, and NH drafted the manuscript; DN, HB, NB, CB, NC, SC, AE, CF, SG, NH, AAH, SH, AH, MH, MI, GJ, AK, JK, NK, RPL, JWL, JMR, MP, JP, KP, AS, JAS, AS, JS, DW, NW, MK, MA, HG, YA processed the manuscript. European data were derived from the European Society for Blood and Marrow Transplantation (EBMT) database for the years 1965–89 and from the EBMT annual activity survey office since 1990. Non- european data were initially provided by the Center for International Blood and Marrow Transplant Research (CIBMTR) since 1964. They were supplemented or replaced by the activity surveys of the Asian Pacific Blood and Marrow Transplantation Group (APBMT) since 1974, the Australasian Bone Marrow Transplant Recipient Registry (ABMTRR) since 1992, the Eastern Mediterranean Blood and Marrow Transplantation Group (EMBMT) since 1984, the Cell Therapy Transplant Canada (CTTC) since 2002, the Latin American Bone Marrow Transplantation Group (LABMT) since 2009, and the African Blood and Marrow Transplant Group (AFBMT) since 2010. Unrelated donor and cord blood information were derived from the World Marrow Donor Association (WMDA) and Bone Marrow Donors Worldwide (BMDW).
Acknowledgments
The cooperation of all participating teams, countries and organ- izations with their staff is greatly appreciated, specifically the fol- lowing: ABMTRR: St. Vincent´s Hospital Sydney, APBMT: Aichi Medical University, CTTC: Centre Tecnològic de Telecomunicacions de Catalunya; CIBMTR: Medical College of Wisconsin, EBMT: Coordination Offices in Barcelona, Paris and London and the Austrian Registry (ASCTR), the Czech BMT Registry, the French Registry (SFGM), the German Registry (DRST), the Italian Registry (GITMO), the Dutch Registry (HOVON), the Spanish BMT Registry (GETH), the Swiss Registry (SBST), the Turkish BMT Registry and the British Registry (BSBMT), EMBMT, SBTMO, LABMT, AFBMT, WMDA, and Eurocord. The authors thank Michael Cross for editorial work on the manuscript.
Funding
Funding for this study was indirectly provided by support of the WBMT. Funding was solely to support the study; no individual payment was made to any of the persons involved in the study. The Activity Survey Office is partly supported by the University Hospital of Basel. MG was supported by SCCER CREST. The Online Supplementary Appendix shows details about funding of the participating institutions.
References
1.Thomas ED, Lochte HL, Lu WC, Ferrebee JW. Intravenous infusion of bone marrow in patients receiving radiation and chemothera- py. New Engl J Med. 1957 (257):491-496.
2. Gratwohl A, Hermans J, Goldman J, et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Lancet. 1998; 352(9134):1087-1092.
3. McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignan- cies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood. 2001;97(11):3390-3400.
4. Bacigalupo A. Second EBMT Workshop on reduced intensity allogeneic hemopoietic stem cell transplants (RI-HSCT). Bone Marrow Transplant. 2002;29(3):191-195.
5. Giralt S, Ballen K, Rizzo D, et al. Reduced- intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for inter- national blood and marrow transplant research. Biol Blood Marrow Transplant. 2009;15(3):367-369.
6. Attal G, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med. 1996;335(2):91-97.
7. Snowden JA, Badoglio M, Labopin M, et al. Evolution, trends, outcomes, and economics of hematopoietic stem cell transplantation in severe autoimmune diseases 4. Blood Adv. 2017;1(27):2742-2755.
8. Gratwohl A, Baldomero H, Aljurf M, et al. Hematopoietic stem cell transplantation: a global perspective. JAMA. 2010; 303(16): 1617-1624.
9. Gratwohl A, Baldomero H, Gratwohl M, et
al. Quantitative and qualitative differences in use and trends of hematopoietic stem cell transplantation: a Global Observational Study. Haematologica. 2013;98(8):1282-290.
10. Gratwohl A, Pasquini MC, Aljurf M, et al. One million haemopoietic stem-cell trans- plants: a retrospective observational study. Lancet Haematol. 2015;2(3):e91-100.
11. Niederwieser D, Baldomero H, Szer J, Gratwohl M, Aljurf M, Atsuta Y, et al. Hematopoietic stem cell transplantation activity worldwide in 2012 and a SWOT analysis of the Worldwide Network for Blood and Marrow Transplantation Group including the global survey. Bone Marrow Transplant. 2016;51(6):778-785.
17. Fakih RE, Greinix H, Koh M, et al. Worldwide Network for Blood and Marrow Transplantation (WBMT) recommendations regarding essential medications required to establish an early stage hematopoietic cell transplantation program. Transplant Cell Ther. 2021;27(3):267.e1-267.e5.
18. Muhsen IN, Hashmi SK, Niederwieser D, et al. Worldwide Network for Blood and Marrow Transplantation (WBMT) perspec- tive: the role of biosimilars in hematopoietic cell transplant: current opportunities and challenges in low- and lower-middle income countries. Bone Marrow Transplant. 2020;55(4):698-707.
19. Pasquini MC, Srivastava A, Ahmed SO, et al. Worldwide Network for Blood and Marrow Transplantation (WBMT) recommendations for establishing a hematopoietic cell trans- plantation program (part I): minimum requirements and beyond. Hematol Oncol Stem Cell Ther. 2020;13(3):131-142.
20.Aljurf M, Weisdorf D, Hashmi SK, et al. Worldwide Network for Blood and Marrow Transplantation (WBMT) recommendations for establishing a hematopoietic stem cell transplantation program in countries with limited resources (part II): clinical, technical and socio-economic considerations. Hematol Oncol Stem Cell Ther. 2020;13(1):7-16.
21. Aljurf M, Weisdorf D, Alfraih F, et al. "Worldwide Network for Blood & Marrow Transplantation (WBMT) special article, challenges facing emerging alternate donor registries". Bone Marrow Transplantat. 2019;54(8):1179-1188.
22. Frutos C, Enciso ME, Glasenapp A von, Quiroz A, Batista J, Niederwieser D. Bridging the gap using telemedicine: optimizing an existing autologous hematopoietic SCT unit into an allogeneic hematopoietic SCT unit in Paraguay with the help of the WBMT. Blood Adv. 2019;3(Suppl 1):S45–7.
12.
Baldomero H, Aljurf M, Zaidi SZA, et al. Narrowing the gap for hematopoietic stem cell transplantation in the East- Mediterranean/African region: comparison with global HSCT indications and trends. Bone Marrow Transplant. 2019;54(3):402- 417.
13. Iida M, Dodds A, Akter MR, et al. The 2016 APBMT Activity Survey Report: trends in haploidentical and cord blood transplanta- tion in the Asia-Pacific region. Blood Cell Therapy. 2021(4):20-28.
14. Niederwieser D. The Chinese HCT survey: a non-manipulated haploidentical transplanta- tion procedure makes a novel contribution to data sharing within the regional and global transplant registries and to worldwide knowledge. Bone Marrow Transplant. 2021;56(6):1229-1231.
15. Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommenda- tions for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966-984.
16. Xu L-P, Wu D-P, Han M-Z, et al. A review of hematopoietic cell transplantation in China: data and trends during 2008-2016 [eng]. Bone Marrow Transplant. 2017; 52(11): 1512-1518.
haematologica | 2022; 107(5)
1053